PuSH - Publication Server of Helmholtz Zentrum München

Tsiverioti, C.A.* ; Gottschlich, A.* ; Theurich, S.* ; Anders, H.J.* ; Kroiss, M.* ; Kobold, S. ; Trefny, M.P.*

Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.

Biol. Chem., DOI: 10.1515/hsz-2023-0317 (2024)
DOI PMC
Creative Commons Lizenzvertrag
Open Access Green as soon as Postprint is submitted to ZB.
Chimeric antigen receptor (CAR)-T cell therapy has led to remarkable clinical outcomes in the treatment of hematological malignancies. However, challenges remain, such as limited infiltration into solid tumors, inadequate persistence, systemic toxicities, and manufacturing insufficiencies. The use of alternative cell sources for CAR-based therapies, such as natural killer cells (NK), macrophages (MΦ), invariant Natural Killer T (iNKT) cells, γδT cells, neutrophils, and induced pluripotent stem cells (iPSC), has emerged as a promising avenue. By harnessing these cells' inherent cytotoxic mechanisms and incorporating CAR technology, common CAR-T cell-related limitations can be effectively mitigated. We herein present an overview of the tumoricidal mechanisms, CAR designs, and manufacturing processes of CAR-NK cells, CAR-MΦ, CAR-iNKT cells, CAR-γδT cells, CAR-neutrophils, and iPSC-derived CAR-cells, outlining the advantages, limitations, and potential solutions of these therapeutic strategies.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Corresponding Author
Keywords Car-nk Cells ; Car-t Cells ; Car-inkt Cells ; Car-macrophages ; Car-neutrophils ; Car-γδt cells; Chimeric-antigen-receptor; Natural-killer-cells; Pluripotent Stem-cells; V-alpha-24-invariant Nkt Cells; Acute Myeloid-leukemia; In-vivo Expansion; Phase-i; Dendritic Cells; Adoptive Immunotherapy; Antitumor-activity
ISSN (print) / ISBN 1431-6730
e-ISSN 1437-4315
Publisher de Gruyter
Publishing Place Genthiner Strasse 13, D-10785 Berlin, Germany
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Unit for Clinical Pharmacology (KKG-EKLiP)
Grants Go-Bio-Initiative